Key Takeaways:
(NEW YORK) – ADMA Biologics, Inc. (NASDAQ:ADMA) is facing a securities fraud investigation from law firm Bleichmar Fonti & Auld LLP, announced on April 20, 2026, which has caused a 29 percent drop in its stock price.
"If you invested in ADMA Biologics, you are encouraged to obtain additional information," the firm stated in their press release.
The investigation centers on claims of "channel stuffing," a practice where a company inflates its sales and earnings figures by forcing more products through a distribution channel than can be sold. The 29 percent stock drop reflects immediate investor concern over the allegations.
The investigation could lead to a class-action lawsuit and significant financial penalties for ADMA Biologics.
The sharp decline in stock price puts ADMA Biologics to its lowest point since October 2025. The company's next major catalyst will be its upcoming earnings report, where management will be expected to address the allegations.
This article is for informational purposes only and does not constitute investment advice.
